Latest Insider Transactions at Contineum Therapeutics, Inc. (CTNM)
This section provides a real-time view of insider transactions for Contineum Therapeutics, Inc. (CTNM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Contineum Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Contineum Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 25
2024
|
Daniel S. Lorrain Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,010
-0.6%
|
$16,160
$16.02 P/Share
|
|
Nov 18
2024
|
Daniel S. Lorrain Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,190
-1.76%
|
$99,040
$16.71 P/Share
|
|
Aug 13
2024
|
Stephen L. Huhn CMO & Sr VP, Clinical Dev. |
BUY
Exercise of conversion of derivative security
|
Direct |
12,800
+50.0%
|
$12,800
$1.01 P/Share
|
|
Apr 09
2024
|
Versant Venture Capital Vi, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
542,628
+50.0%
|
-
|